European Heart Journal. Cardiovascular Pharmacotherapy
Overview
European Heart Journal. Cardiovascular Pharmacotherapy is a scientific journal, published by Oxford University Press since 2015 in English. The journal's country of origin is United Kingdom.
Details
Details
Abbr.
Eur Heart J Cardiovasc Pharmacother
Publisher
Oxford University Press
Start
2015
End
Continuing
Frequency
Quarterly
p-ISSN
2055-6837
e-ISSN
2055-6845
Country
United Kingdom
Language
English
Metrics
Metrics
h-index / Ranks: 8709
40
SJR / Ranks: 1943
1507
CiteScore / Ranks: 1834
8.90
JIF / Ranks: 853
7.1
Recent Articles
1.
Laudani C, Abbate A, Angiolillo D, Galli M
Eur Heart J Cardiovasc Pharmacother
. 2025 Mar;
PMID: 40080070
No abstract available.
2.
Agewall S
Eur Heart J Cardiovasc Pharmacother
. 2025 Mar;
11(2):105-106.
PMID: 40079901
No abstract available.
3.
Gragnano F, Cesaro A, Galli M, Calabro P
Eur Heart J Cardiovasc Pharmacother
. 2025 Mar;
PMID: 40063336
No abstract available.
4.
Tamargo J, Agewall S, Ambrosio G, Borghi C, Cerbai E, Dan G, et al.
Eur Heart J Cardiovasc Pharmacother
. 2025 Mar;
PMID: 40058879
Despite substantial advances in cardiovascular pharmacotherapy and devices in recent years, prevention and treatment of many cardiovascular diseases (CVD) remain limited, thus reflecting the need for more effective and safer...
5.
Parhofer K, Aguiar C, Banach M, Drexel H, Gouni-Berthold I, de Isla L, et al.
Eur Heart J Cardiovasc Pharmacother
. 2025 Mar;
PMID: 40052330
The clinically important link between low-density lipoprotein cholesterol (LDL-C) lowering and cardiovascular (CV) risk reduction is well-established and reflected in the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines for...
6.
Bogoviku J, Nguyen T, Westphal J, Aftanski P, Moebius-Winkler S, Haertel F, et al.
Eur Heart J Cardiovasc Pharmacother
. 2025 Mar;
11(2):190-197.
PMID: 40037298
Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve prognosis in chronic heart failure as part of currently recommended therapeutic strategies. Transthoracic echocardiography (TTE) is frequently used to assess heart function and...
7.
Liaigre L, Guigui A, Manceau M, Cracowski J, Khouri C, Roustit M
Eur Heart J Cardiovasc Pharmacother
. 2025 Feb;
PMID: 39999862
Aims: Low-density lipoprotein cholesterol (LDL-c) and non-high-density lipoprotein cholesterol (non-HDL-c) are prognostic factors of cardiovascular risk. However, their validity as trial-level surrogates for cardiovascular outcomes is debated. This study aimed...
8.
Chen S, Wu J, Liao K, Lin Y
Eur Heart J Cardiovasc Pharmacother
. 2025 Feb;
PMID: 39963713
Aims: Managing patients with atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) is challenging. While sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) show cardiovascular benefits,...
9.
Le N, Tran T, McClure J, Gill D, Padmanabhan S
Eur Heart J Cardiovasc Pharmacother
. 2025 Feb;
PMID: 39963705
Aims: Emerging antihypertensive drug classes offer new opportunities to manage hypertension, however, their long-term effects on cardiovascular, kidney and metabolic (CKM) outcomes remain to be elucidated. This study aims to...
10.
Lin Y, Wu J, Lee M, Su C, Toh H, Chang W, et al.
Eur Heart J Cardiovasc Pharmacother
. 2025 Feb;
11(2):174-189.
PMID: 39923808
Background: Atherosclerotic cardiovascular disease (ASCVD) encompasses various phenotypes with elevated risks of major adverse cardiovascular events (MACEs). This study aimed to assess the comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor...